Pfizer announces new UK Managing Director

pharmafile | December 10, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ben Osborne, EU, Leeds, Pfizer, sales 

New York City-based multinational Pfizer has announced the appointment of Ben Osborn to the role of managing Director in the UK and Cluster Lead Europe within Pfizer’s Established Medicines business.

The Leeds University graduate and long-term Pfizer employee will take over from pharma veteran Erik Nordkamp who led the UK branch for almost four years.

Osborn joined Pfizer in 1998 taking on roles of increasing seniority before taking on a leadership role as the head of the marketing organisation within Pfizer’s Innovative Medicines business at a regional level in 2015.

Prior to this the Physiology and Sports Science grad acted as Head of Oncology in the UK where he assisted in shaping UK cancer policy through his work with Government, patient groups and as a co-chair of the ABPI’s cancer group.

Osborn commented: “I am delighted to be returning to the UK business and to be taking on the role of UK Managing Director at such an important time.  With the NHS at a critical moment in the development of its long-term plan, a new era of partnership between the health service and industry will be vital to achieving the best for UK patients.  We are, therefore, very keen to develop new and build on existing relationships with Government and the NHS to try and help deliver this.”

Nordkamp will continue in his work at the ABPI and retain his position as the organisation’s President until April 2019. While working at Pfizer Nordkamp also chaired the American Pharmaceutical Group.

Nordkamp commented: “It has been a tremendous privilege to lead the UK Company and while it has undoubtedly been challenging, it has also been immensely rewarding.  Pfizer is committed to partnering with the NHS to improve the delivery of healthcare and achieve the best health outcomes for people in the UK.  We must all work together to create an innovation-ready health service by finding new ways to embrace next-generation ideas and technologies that can transform care and improve lives while creating efficiencies within the health system.”

Related Content

Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment

Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination …

CDC Advisory Committee recommends Pfizer’s RSV vaccine

Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee …

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their …

Latest content